Ikena Selling General Administrative vs Operating Income Analysis

IKNA Stock  USD 1.70  0.03  1.80%   
Ikena Oncology financial indicator trend analysis is infinitely more than just investigating Ikena Oncology recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ikena Oncology is a good investment. Please check the relationship between Ikena Oncology Selling General Administrative and its Operating Income accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ikena Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.

Selling General Administrative vs Operating Income

Selling General Administrative vs Operating Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ikena Oncology Selling General Administrative account and Operating Income. At this time, the significance of the direction appears to have pay attention.
The correlation between Ikena Oncology's Selling General Administrative and Operating Income is -0.9. Overlapping area represents the amount of variation of Selling General Administrative that can explain the historical movement of Operating Income in the same time period over historical financial statements of Ikena Oncology, assuming nothing else is changed. The correlation between historical values of Ikena Oncology's Selling General Administrative and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Selling General Administrative of Ikena Oncology are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Selling General Administrative i.e., Ikena Oncology's Selling General Administrative and Operating Income go up and down completely randomly.

Correlation Coefficient

-0.9
Relationship DirectionNegative 
Relationship StrengthSignificant

Selling General Administrative

Operating Income

Operating Income is the amount of profit realized from Ikena Oncology operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Ikena Oncology is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.
Most indicators from Ikena Oncology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ikena Oncology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ikena Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.At present, Ikena Oncology's Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 2.86, whereas Selling General Administrative is forecasted to decline to about 17.9 M.
 2021 2022 2023 2024 (projected)
Total Operating Expenses65.1M86.5M84.6M70.9M
Cost Of Revenue47.1M2.0M1.0M969K

Ikena Oncology fundamental ratios Correlations

0.770.320.72-0.850.020.920.90.530.920.88-0.980.740.85-0.7-0.780.470.870.830.870.820.5-0.490.95-0.490.74
0.770.760.51-0.61-0.430.880.90.070.610.79-0.820.560.63-0.42-0.80.620.610.60.790.550.27-0.270.71-0.260.56
0.320.76-0.08-0.17-0.810.420.45-0.440.160.24-0.35-0.020.06-0.03-0.340.280.080.130.250.030.030.240.210.24-0.02
0.720.51-0.08-0.860.120.750.780.850.850.85-0.731.00.96-0.82-0.650.430.950.880.830.940.66-0.930.87-0.931.0
-0.85-0.61-0.17-0.860.05-0.79-0.8-0.69-0.91-0.820.84-0.88-0.870.970.63-0.3-0.92-0.99-0.8-0.87-0.850.74-0.930.75-0.88
0.02-0.43-0.810.120.05-0.04-0.120.370.00.1-0.050.080.070.02-0.120.160.050.020.10.05-0.03-0.050.04-0.050.08
0.920.880.420.75-0.79-0.040.990.460.850.97-0.970.780.86-0.61-0.940.740.850.80.980.810.47-0.480.93-0.470.78
0.90.90.450.78-0.8-0.120.990.480.860.97-0.950.810.88-0.64-0.920.730.870.810.970.830.49-0.530.93-0.520.81
0.530.07-0.440.85-0.690.370.460.480.780.6-0.490.830.81-0.71-0.370.210.830.690.570.870.6-0.860.71-0.860.83
0.920.610.160.85-0.910.00.850.860.780.85-0.870.860.94-0.81-0.680.40.970.880.830.960.64-0.710.97-0.710.86
0.880.790.240.85-0.820.10.970.970.60.85-0.940.870.91-0.67-0.950.760.890.851.00.860.53-0.60.94-0.60.87
-0.98-0.82-0.35-0.730.84-0.05-0.97-0.95-0.49-0.87-0.94-0.75-0.850.680.89-0.62-0.85-0.84-0.94-0.8-0.520.45-0.950.45-0.75
0.740.56-0.021.0-0.880.080.780.810.830.860.87-0.750.97-0.83-0.680.450.960.890.850.950.66-0.920.89-0.921.0
0.850.630.060.96-0.870.070.860.880.810.940.91-0.850.97-0.78-0.730.50.990.870.90.990.58-0.840.95-0.840.97
-0.7-0.42-0.03-0.820.970.02-0.61-0.64-0.71-0.81-0.670.68-0.83-0.780.45-0.12-0.83-0.96-0.65-0.79-0.930.77-0.820.79-0.83
-0.78-0.8-0.34-0.650.63-0.12-0.94-0.92-0.37-0.68-0.950.89-0.68-0.730.45-0.91-0.71-0.68-0.96-0.67-0.380.34-0.810.33-0.68
0.470.620.280.43-0.30.160.740.730.210.40.76-0.620.450.5-0.12-0.910.440.370.780.440.12-0.130.54-0.120.45
0.870.610.080.95-0.920.050.850.870.830.970.89-0.850.960.99-0.83-0.710.440.910.880.990.66-0.830.97-0.830.96
0.830.60.130.88-0.990.020.80.810.690.880.85-0.840.890.87-0.96-0.680.370.910.830.860.87-0.740.93-0.750.89
0.870.790.250.83-0.80.10.980.970.570.831.0-0.940.850.9-0.65-0.960.780.880.830.840.51-0.570.93-0.570.85
0.820.550.030.94-0.870.050.810.830.870.960.86-0.80.950.99-0.79-0.670.440.990.860.840.62-0.850.94-0.850.95
0.50.270.030.66-0.85-0.030.470.490.60.640.53-0.520.660.58-0.93-0.380.120.660.870.510.62-0.60.67-0.630.66
-0.49-0.270.24-0.930.74-0.05-0.48-0.53-0.86-0.71-0.60.45-0.92-0.840.770.34-0.13-0.83-0.74-0.57-0.85-0.6-0.681.0-0.92
0.950.710.210.87-0.930.040.930.930.710.970.94-0.950.890.95-0.82-0.810.540.970.930.930.940.67-0.68-0.680.89
-0.49-0.260.24-0.930.75-0.05-0.47-0.52-0.86-0.71-0.60.45-0.92-0.840.790.33-0.12-0.83-0.75-0.57-0.85-0.631.0-0.68-0.92
0.740.56-0.021.0-0.880.080.780.810.830.860.87-0.751.00.97-0.83-0.680.450.960.890.850.950.66-0.920.89-0.92
Click cells to compare fundamentals

Ikena Oncology Account Relationship Matchups

Ikena Oncology fundamental ratios Accounts

201920202021202220232024 (projected)
Other Current Liab121K5.0M4.0M6.4M5.0M3.8M
Total Current Liabilities24.3M28.3M27.2M21.5M14.2M21.9M
Net Tangible Assets(61.5M)(101.0M)207.9M147.0M169.0M177.5M
Retained Earnings(67.1M)(111.3M)(145.5M)(214.2M)(282.4M)(268.3M)
Accounts Payable935K2.1M2.4M2.1M2.1M2.2M
Other Current Assets1.3M3.5M4.3M3.1M3.2M2.9M
Total Current Assets85.2M166.0M236.5M160.0M178.7M155.2M
Property Plant Equipment769K1.6M2.4M3.2M3.7M1.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Ikena Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ikena Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ikena Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ikena Oncology Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ikena Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ikena Oncology. If investors know Ikena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ikena Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.23)
Revenue Per Share
0.014
Quarterly Revenue Growth
(0.88)
Return On Assets
(0.22)
Return On Equity
(0.37)
The market value of Ikena Oncology is measured differently than its book value, which is the value of Ikena that is recorded on the company's balance sheet. Investors also form their own opinion of Ikena Oncology's value that differs from its market value or its book value, called intrinsic value, which is Ikena Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ikena Oncology's market value can be influenced by many factors that don't directly affect Ikena Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ikena Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ikena Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ikena Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.